Industry
Biotechnology
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
February 20, 2024 | 5:09 pm
Portfolio Pulse from Avi Kapoor
February 15, 2024 | 12:57 pm
Portfolio Pulse from Avi Kapoor
February 14, 2024 | 7:32 pm
Portfolio Pulse from Avi Kapoor
February 14, 2024 | 6:18 pm
Portfolio Pulse from Benzinga Newsdesk
February 14, 2024 | 4:21 pm
Portfolio Pulse from Henry Khederian
February 14, 2024 | 1:36 pm
Portfolio Pulse from Benzinga Newsdesk
February 14, 2024 | 11:53 am
Portfolio Pulse from Benzinga Newsdesk
February 14, 2024 | 11:49 am
Portfolio Pulse from Benzinga Newsdesk
January 29, 2024 | 12:17 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.